Given the volume of funds that were quickly dispersed during the COVID-19 pandemic, there were plenty of new areas for fraud and abuse. The Department of Justice (“DOJ”) initially set its sights on targeting the borrowers of such funds. Now, the DOJ is ramping up enforcement with the first ever False Claims Act (“FCA”) settlement with a lender of Paycheck Protection Programs (“PPP”) funds.

Spurred by the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act authorized the issuance of PPP loans in order to provide relief to small businesses experiencing economic hardship during the pandemic. It was expected that those loans would be forgiven if certain conditions were met. Lenders originating the PPP loans were entitled to receive a fixed fee from the Small Business Administration (“SBA”), ranging from 1% to 5% depending on the size of the loan.

At the onset of the program, Lenders of such PPP loans were  concerned with the potential for private lawsuits from would-be borrowers on the basis of bank lending practices, and not with government enforcement. As I have written about before, initially, the government enforcement in this space focused solely on borrowers, who allegedly made false statements in connection with obtaining loans. However, on September 13th of this year, the DOJ revealed an expanded focus, targeting the lenders of PPP loans as well as the borrowers in an FCA settlement. In a press release the U.S. Attorney’s Office for the Southern District of Texas announced that a PPP lender, Prosperity Bank, had agreed to pay $18,673.50 to resolve allegations it improperly processed a PPP loan on behalf of an ineligible customer, Woodlands Pain Institute PLLC (“Woodlands”).

According to the press release, Woodlands applied for a PPP loan in the amount of $213,400, which was processed and approved by Prosperity Bank in May of 2020. The application for the loan included a question asking whether the applicant (or any individual owning more than 20% equity) was subject to an indictment, criminal information, arraignment or other means by which formal criminal charges are brought in any jurisdiction.

The government alleged that at the time of application, the sole owner of Woodlands, Dr. Emad Bishai, was facing criminal charges arising from his practice of prescribing opioid medicines. Bishai was arrested in November of 2019 under allegations that he committed unprofessional or dishonorable conduct by prescribing to a person he knew or should have known was an abuser of controlled substances and of prescribing without a medical purpose, according to the Montgomery County District Attorney’s Office. Despite his arrest, when filling out the application for the PPP loan, Bishai checked the box marked “No” and initialed his name beneath the question. Bishai was formally indicted in August of 2020.

When the application was processed, Prosperity Bank employees knew Bishai was ineligible to apply for the PPP loan due to the pending criminal charges against him. However, the bank processed the application containing the false representation anyway and ultimately granted the money to Bishai. As a result of the false application, Prosperity Bank received a 5% processing fee of $10,670 from the government. Bishai separately entered into a settlement for $523,331 in November 2021 to resolve his liability arising from submission of false claims for the placement of electro-acupuncture devices and his submission of the fraudulent PPP loan application. He also repaid the PPP loan in full in 2022.

The FCA settlement with Woodlands is an example of the government’s continuing enforcement focus on fraud in the COVID-19 space, and suggests that enforcement efforts are not slowing down, rather they are expanding to new targets and using new tools such as the FCA.  Indeed, there is certainly the possibility for a flood of PPP-related qui tam suits brought by whistleblowers, acting as relators on behalf of the government. Considering the expanded focus of enforcement, financial institutions involved in lending COVID-19 relief funding should take great care to ensure the eligibility of applicants, or risk becoming a target for government enforcement and significant civil or criminal consequences. Similarly, those who obtained COVID-19 relief funds through PPP loans should take great care when utilizing such funding.

Back to Commercial Litigation Update Blog

Search This Blog

Blog Editors

Authors

Related Services

Topics

Archives

Jump to Page

Subscribe

Sign up to receive an email notification when new Commercial Litigation Update posts are published:

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.